Pill Identifier App

Prevnar 13 Sales Data

Rank 81 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Prevnar 13 U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 81 (7) 6.41% 6.51%
Q3 2013 88 (3) 2.75% 3.05%
Q2 2013 85 (10) 6.00% 6.49%
Q1 2013 95 (15) -11.69% -13.97%
Q4 2012 80 (14) 15.24% 13.29%
Q3 2012 94 (10) -5.86% -5.39%
Q2 2012 84 (8) 5.30% 7.74%
Q1 2012 92 (4) -1.16% -5.49%
Q4 2011 88 (11) -6.93% -7.87%
Q3 2011 77 ()
Q1 2011 60

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
February 22, 2012Pfizer Statement Regarding CDC's ACIP Discussion of Prevnar 13 for Use in Adults
January 3, 2012Prevnar 13 Pneumonia Vaccine Approved for Older People
January 3, 2012FDA Approves Pneumococcal 13 Vaccine
November 17, 2011FDA Panel Backs Pfizer Vaccine for Adults
February 24, 2010Successor to Combination Pneumococcal Vaccine Approved
Hide
(web1)